2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMORecruiting
Primary objective:Demonstrate the analgesic efficacy of intra-articular RTX-GRT7039 compared with placebo.Secondary objective:• Demonstrate the analgesic efficacy of intra-articular RTX-GRT7039 compared with placebo.• Demonstrate the efficacy of…